Hürzeler C, von Felten A
Departement Innere Medizin, Universitätsspital Zürich.
Schweiz Med Wochenschr. 1994 Apr 30;124(17):712-9.
The activated partial thromboplastin time (aPTT, PTT) is widely used to monitor therapeutic anticoagulation with standard heparin. However, it has been known for some time that PTT reagents obtained from various manufacturers display different sensitivities to heparin--a fact which often is not taken into account. The study deals with the question whether the sensitivity of the PTT to heparin is additionally influenced by the decrease in the vitamin K-dependent coagulation factors such as occurs after starting oral anticoagulation (OAC). In in-vitro studies the reaction of the PTT was observed after addition of different amounts of heparin to normal plasma, to plasma taken after the start of OAC and during stable OAC. The results show that the PTT tends to be more sensitive to heparin as soon as oral anticoagulation is initiated. This phenomenon already occurs at an early stage of anticoagulant intake where only factor VII is markedly reduced but prothrombin concentration is still in an almost normal range and therefore a clinically sufficient effect of OAC is not to be expected. Identical results are obtained with plasma samples of heparin treated patients before and after the start of OAC; in addition, a scattering of the PTTs is obvious. This leads to overestimation of heparin concentrations and a consequent reduction of dosage at an early, still insufficient stage of OAC. In contrast, the thrombin time shows--independently of OAC--a good correlation to heparin concentrations. Therefore the thrombin time is more appropriate to monitor heparin therapy in the phase when oral anticoagulation is started.
活化部分凝血活酶时间(aPTT,PTT)被广泛用于监测标准肝素的治疗性抗凝效果。然而,一段时间以来人们已经知道,不同厂家生产的PTT试剂对肝素的敏感性不同——这一事实常常未被考虑在内。本研究探讨了PTT对肝素的敏感性是否会受到维生素K依赖性凝血因子减少的额外影响,例如在开始口服抗凝治疗(OAC)后所发生的情况。在体外研究中,观察了向正常血浆、OAC开始后采集的血浆以及稳定OAC期间采集的血浆中添加不同量肝素后PTT的反应。结果表明,一旦开始口服抗凝治疗,PTT对肝素的敏感性往往会更高。这种现象在抗凝剂摄入的早期阶段就已出现,此时只有因子VII明显降低,但凝血酶原浓度仍几乎处于正常范围,因此预计OAC的临床效果并不充分。在OAC开始前后,肝素治疗患者的血浆样本也得到了相同的结果;此外,PTT值存在明显离散。这导致在OAC早期且效果仍不充分的阶段高估肝素浓度,进而减少剂量。相比之下,凝血酶时间显示——与OAC无关——与肝素浓度具有良好的相关性。因此,在开始口服抗凝治疗阶段,凝血酶时间更适合用于监测肝素治疗。